The playbook
Evidence-based articles on testosterone, metabolic health, and the science behind what actually works.
A single testosterone number is not a diagnosis. This guide explains common markers on a men's hormone panel, why morning confirmation matters, and where lab science still has limits. It does not recommend starting, stopping, or dosing any medication.
Read moreSemaglutide (GLP-1 receptor agonist) and tirzepatide (dual GIP/GLP-1 receptor agonist) are among the best-studied medicines for chronic weight management when used with diet and activity. This article summarizes mechanisms, major trials, and safety themes. It cannot choose a drug for you. Compounded versions of these ingredients are not FDA-approved.
Read moreInterest in pairing testosterone therapy (TRT) with GLP-1–based weight-loss medicines is high among men over 35 who want fat loss without "looking flat." That goal is understandable. High-quality trials of the combination as a deliberate "stack" remain limited. This piece separates established science from marketing language.
Read moreExogenous testosterone commonly suppresses luteinizing hormone (LH), follicle-stimulating hormone (FSH), and spermatogenesis. Men who may want biological children need that fact upfront. Enclomiphene citrate has been studied as a selective estrogen receptor modulator (SERM) approach to raise testosterone while better preserving sperm counts than testosterone gel in some trials—but enclomiphene is not FDA-approved, and FDA previously declined approval (Complete Response Letter, 2015).
Read moreAfter 30, cardiometabolic and hormone-related risks accumulate quietly. Knowing a short list of markers helps you ask better questions—not diagnose yourself or order hormones from a graph. Screening decisions (especially PSA) are individualized.
Read moreMeaningful weight loss on GLP-1 or dual GIP/GLP-1 medicines includes loss of fat mass and some lean mass. Lean mass on DXA is not identical to skeletal muscle, but the concern is real—especially for men over 35 who care about strength and long-term function. This article summarizes evidence and practical safeguards. It is not a prescription for stacking anabolic drugs.
Read moreGLP-1 medicines may help some men with obesity-related low testosterone mainly by supporting weight loss and better metabolic health, not by acting as testosterone or fertility medicines. Testosterone may improve as obesity and insulin resistance improve, but the evidence is still limited. When compounded semaglutide/tirzepatide is used, it is compounded and filled by a licensed 503A pharmacy and is not the FDA-approved brand (Ozempic, Wegovy, Mounjaro, Zepbound, etc.). This is education only, not a diagnosis or treatment plan.
Read moreLow testosterone ("Low T," or male hypogonadism) means symptoms consistent with androgen deficiency plus morning blood testosterone that is consistently low on repeat testing — not one lab printout. The Endocrine Society's 2018 guideline frames diagnosis that way: compatible signs and symptoms with unequivocally and consistently low morning testosterone. A single number, an afternoon draw, or symptoms alone does not prove Low T.
Read moreTRT cost depends on labs, medication (FDA-approved commercial products vs compounded preparations), follow-up visits, and how monitoring is bundled — not a single sticker price. Online / telehealth TRT is clinician evaluation plus prescribing when appropriate, not a vending machine. A low monthly quote alone does not prove medical indication, product quality, or that monitoring is adequate.
Read moreBPC-157 is a synthetic 15–amino-acid peptide studied mainly in animals for tissue and gut repair. It is not an FDA-approved drug. Compounded versions sit in an unsettled regulatory lane, and research-use-only products marketed for humans are a separate high-risk category. Sparse human studies do not automatically prove everyday recovery, injury, or "healing" claims in men. Scoreboard does not currently offer BPC-157; this page is education only.
Read moreCJC-1295 and Ipamorelin are two peptides often paired as a growth-hormone–axis "stack" in men's optimization culture. Compounded versions are not FDA-approved finished drugs for muscle, recovery, fat-loss, or anti-aging uses. Single-ingredient trial signals do not automatically prove the combination — and this stack is not equivalent to FDA-approved growth hormone (somatropin) or other labeled GH products. Scoreboard does not currently offer CJC-1295, Ipamorelin, or this stack; this page is education only.
Read moreBPC-157 and TB-500 are two lab-made peptides often paired as the "Wolverine stack." Prescribed versions are compounded, not FDA-approved. On October 30, 2026, HHS said it will not, for now, take enforcement action against certain 503A compounding of these peptides. That opens a legal path for some prescriptions. It does not prove the peptides are safe or that they work, and it does not cover a combined two-peptide vial.
Read moreGet a comprehensive lab panel and clinician review. No guesswork, no generic protocols.
Request a Consultation